Premium
Therapeutic targets of triple‐negative breast cancer: a review
Author(s) -
Jamdade Vinayak S,
Sethi Nikunj,
Mundhe Nitin A,
Kumar Parveen,
Lahkar Mangala,
Sinha Neeraj
Publication year - 2015
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13211
Subject(s) - triple negative breast cancer , breast cancer , hedgehog , medicine , cancer , cancer research , angiogenesis , pi3k/akt/mtor pathway , oncology , bioinformatics , signal transduction , biology , biochemistry
Breast cancer ( BC ) is the second most common cause of cancer deaths. Triple‐negative breast cancer ( TNBC ) does not show immunohistochemical expression of oestrogen receptors, progesterone receptors or HER2. At present, no suitable treatment option is available for patients with TNBC . This dearth of effective conventional therapies for the treatment of advanced stage breast cancer has provoked the development of novel strategies for the management of patients with TNBC . This review presents recent information associated with different therapeutic options for the treatment of TNBC focusing on promising targets such as the Notch signalling, W nt/β‐catenin and Hedgehog pathways, in addition to EGFR , PARP1 , mTOR , TGF ‐β and angiogenesis inhibitors.